{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:26:47Z","timestamp":1770712007090,"version":"3.49.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"F2G Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Early antifungal initiation in invasive aspergillosis (IA) is recommended. Changing antifungals occurs for a myriad of reasons but associated costs are unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>US claims data for adults admitted for IA were identified from 10\/1\/2015 to 11\/30\/2022. Patients were stratified by those who did and did not change antifungal therapy. Adjusted all-cause healthcare utilization and costs\/patient during index hospitalization and at 1, 6, and 12-months after the index date between the cohorts that did and did not change antifungal therapy were compared.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 1,192 IA patients, 707 (59.3%) changed their initial antifungal therapy over follow-up. The index hospital length of stay was longer (\u0394 = 6 days, P &amp;lt; .001) and costs were higher (\u0394 = $65,149, P &amp;lt; .001) in the change vs. no change cohort. Median 1, 6, and 12-months all-cause costs were higher in patients changing antifungal therapy vs. not (\u0394 = $90,938\u2212$192,953).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Changing antifungals was associated with longer hospital stays and costs and higher all-cause costs over 12-months.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae747","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T19:22:52Z","timestamp":1734722572000},"source":"Crossref","is-referenced-by-count":1,"title":["Association Between the Need to Change Initial Antifungal Therapy and Treatment Costs in Patients With Invasive Aspergillosis"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5868-0529","authenticated-orcid":false,"given":"Barbara D","family":"Alexander","sequence":"first","affiliation":[{"name":"Infectious Diseases Division, Duke University , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6606-9460","authenticated-orcid":false,"given":"Melissa","family":"Johnson","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Duke University , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bresnik","sequence":"additional","affiliation":[{"name":"F2G, Inc. , Princeton, New Jersey ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0385-8657","authenticated-orcid":false,"given":"Vamshi Ruthwik","family":"Anupindi","sequence":"additional","affiliation":[{"name":"IQVIA , Falls Church, Virginia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia","family":"Pizzicato","sequence":"additional","affiliation":[{"name":"IQVIA , Falls Church, Virginia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-6202","authenticated-orcid":false,"given":"Mitchell","family":"DeKoven","sequence":"additional","affiliation":[{"name":"IQVIA , Falls Church, Virginia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"Lovelace","sequence":"additional","affiliation":[{"name":"F2G, Inc. , Princeton, New Jersey ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-7158","authenticated-orcid":false,"given":"Craig I","family":"Coleman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, University of Connecticut , Storrs, Connecticut ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"2025031806470696300_ofae747-B1","doi-asserted-by":"crossref","first-page":"ofac097","DOI":"10.1093\/ofid\/ofac097","article-title":"Economic burden of fungal diseases in the United States","volume":"9","author":"Benedict","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025031806470696300_ofae747-B2","volume-title":"WHO fungal priority pathogens list to guide research, development, and public health action","author":"World Health Organization","year":"2022"},{"key":"2025031806470696300_ofae747-B3","doi-asserted-by":"crossref","first-page":"ofab593","DOI":"10.1093\/ofid\/ofab593","article-title":"Prevalence and healthcare burden of fungal infections in the United States, 2018","volume":"9","author":"Rayens","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025031806470696300_ofae747-B4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025031806470696300_ofae747-B5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"2025031806470696300_ofae747-B6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijid.2008.02.013","article-title":"The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups","volume":"13","author":"Tong","year":"2009","journal-title":"Int J Infect Dis"},{"key":"2025031806470696300_ofae747-B7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/jac\/dkab317","article-title":"When to change treatment of acute invasive aspergillosis: an expert viewpoint","volume":"77","author":"Slavin","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025031806470696300_ofae747-B8","doi-asserted-by":"crossref","first-page":"e0072123","DOI":"10.1128\/aac.00721-23","article-title":"Treatment pathways, switches, and inappropriate treatment during invasive pulmonary aspergillosis: real-world experiences from a global research network study","volume":"67","author":"Henao-Martinez","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031806470696300_ofae747-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13696998.2020.1845185","article-title":"Healthcare resource utilization and exacerbations in patients with chronic obstructive pulmonary disease treated with nebulized glycopyrrolate in the USA: a real-world data analysis","volume":"24","author":"Niu","year":"2021","journal-title":"J Med Econ"},{"key":"2025031806470696300_ofae747-B10","author":"IQVIA"},{"key":"2025031806470696300_ofae747-B11","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2025031806470696300_ofae747-B12","first-page":"215","article-title":"Administrative databases and outcomes assessment: an overview of issues and potential utility","volume":"5","author":"Gandhi","year":"1999","journal-title":"J Manag Care Pharm"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae747\/61249460\/ofae747.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/1\/ofae747\/61249460\/ofae747.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/1\/ofae747\/61249460\/ofae747.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T06:47:21Z","timestamp":1742280441000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae747\/7929832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae747","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,12,20]]},"article-number":"ofae747"}}